Welcome back to Plenary Session. This is the podcast at the intersection of medicine,

oncology, and health policy. I'm Dr. Vinay Prasad. I'm professor of medicine here at the

University of California, San Francisco. I'm a practicing hemank doc, and I'm interested in everything

in health policy and evidence-based medicine. And that's what you get on this podcast. Now listen,

I'll be at Ash this year. If you have abstracts you want me to cover, email them at plenary session podcast at gmail.com.

I'm going to try to hit all the big ones.

I'm going to have videos on YouTube as fast as I can put them out.

If you like this podcast, if you're someone out there who's been listening for years,

and you haven't yet written a review on the iTunes store, go ahead and do it.

If you haven't recommended to a friend, do that as well.

This is a podcast that tries to offer something different.

And we'll do that in this episode.

This episode's got two parts.

For 30 minutes, I'm going to take you through a Twitter battle between Dr. Aaron Goodman, Dr. Vincent Raj Kumar. This is about should I treat

high-risk smoldering myeloma? You won't want to miss this battle. And then I'm going to

walk you through a new paper out in JAMA Network Open, a critical appraisal of a paper that compares

people who came in with symptoms and they tested positive for COVID and those who came in

tested negative for COVID. It follows them three months later, and it asks long COVID versus long URI.

So we've got Raj Kumar versus Goodman, long COVID versus long URI.

Stay tuned.

This is going to be a great episode of Plenary Session.

Welcome back.

...